The Tiger Dashboard – July 2026
I’m sharing this month’s DASHBOARD—the same intelligence I use to track new startups currently punching above their weight, M&A and […]
[Tiger’s Weekly Intel] – Meduloc funding, BoneSupport Reimbursement, Pediatric Expansions
This is the kind of week I like to see. No flashy billion-dollar distractions—just real companies solving real problems and
How Many Employees Do You Really Need?
One simple metric is to measure the number of W2s per $1M of revenue. So what is appropriate as an
How Startups can play and win with Strategics.
In our latest BoneChat roundtable, we I sat down with the king of strategic deals, Mike Minette. Read about Mike’s
We have entered “ortho consolidation season” driven mostly by survival.
If you’ve been tracking deal flow across orthopedics, spine, and regenerative medicine over the past few months, you’ve probably noticed
Portable > Local
If you want to predict which ortho companies will scale and which will stall out in capital committees, ignore the
The quiet $350M biologics acquisition and why it happened.
While most of the ortho world was looking the other way, MiMedx (MDXG) quietly pulled the trigger on acquiring Sanara
🔴 Tiger’s Red-Hot Innovator of the Week – Michigan startup is closing the recovery gap after TKA.
“Joint replacement is one of the most successful procedures in modern medicine… until the patient walks out of the OR.“
[Tiger’s Weekly Intel] – Key Regulatory Clearances, IP Acquisitions, and M&A Activity
As we close out July 2026, our industry demonstrated steady momentum. Rather than large-scale venture funding rounds, activity centered on
Why Single-Product Ortho Startups Get Trapped at the Local Maximum
Every orthopedic entrepreneur dreams of the endless upward slope. You build a strong first product, clear regulatory hurdles, win champion
The Death of the “Me-Too” Implant: 4 Startup Megatrends Dominating 2026
If you follow the venture flow in orthopedics, you already know the era of the “me-too” implant is dead. Pure
Sharing real-world playbooks from Ortho Founders
I try to be useful for the ortho entrepreneur. The goal of this blog posting is simple: pull back the
🔴 Tiger’s Red-Hot Innovator of the Week – San Diego spine startup has created an integrated ecosystem for ASCs
Surgical hardware and digital intelligence are converging. In particular, we are watching ortho/spine market reach an inflection point, driven by
[Tiger’s Weekly Intel] – Some Startups found progress through acquisitions, FDA clearances, capital funding, and commercial momentum.
The past week highlighted key momentum across both U.S. and international orthopedic startups, marked by big M&A acquisitions, navigation clearances,
Agency is the real prize.
Agency is the real prize. Not status. Not the title. Not the salary line that shrinks with inflation every year
How Ortho startups can break through the Hospital lockout.
Let’s face it. All the innovation in orthopedics comes from startups these days. However, your better technology and better outcomes
Founders Beware ! Funding scammers are targeting Medtech startups
This is really happening. Learn about it and beware. Let’s face it: the current capital-raising environment for early-stage orthopedic and
Financial Health: What to check before you join a new company.
This is important… and often overlooked. In orthopedics, we love to talk about clinical data, disruptive tech, and market opportunity.
The Strategy Behind the DePuy X-PAC Acquisition
DePuy Synthes announced its acquisition of Expanding Innovations (EI), officially bringing the X-PAC® expandable interbody platform under the DPY umbrella.
🔴 Tiger’s Red-Hot Innovator of the Week: UK startup brings predictive real-time protection to your knee.
This week we are shifting the Sports Med innovation discussion from passive bracing —> to predictive real-time knee protection. Historically,
[Tiger’s Weekly Intel] – M&A, Handheld Robotics, and 3D Biomimetic Implants Drive the Shift to ASC-Focused Outpatient Care
Most of the industry is reading self-serving press releases, but here is your intel for the week. The trend continues
How to torch $300M building a surgical robot company.
It is one of the most seductive pitches in modern venture capital: “We are going to disrupt Intuitive Surgical’s DaVinci.”
The Great Unbundling of Orthopedics Has Begun
For decades, the dominant orthopedic corporate strategy was portfolio consolidation—creating “one-stop-shop” conglomerates that could bundle joints, spine, trauma, and sports
The Brutal 10-Year Verdict: How Shaving the Meniscus Actually Ruins the Knee
Article Summary The orthopedic industry just got handed a 10-year bill it can’t ignore. For decades, arthroscopic partial meniscectomy was
🔴 Tiger’s Red-Hot Innovator of the Week – French startup simplifying ACJ stabilization with synthetic ligament.
I believe that we are entering the Sports Med wave with accelerating innovation in this space. Here is my scoring
[Tiger’s Weekly Intel] – VB Spine’s acquisition, Movmedix’s FDA clearance, and Miach’s clinical data.
Most of the industry is reading self-serving press releases, but here is your intel on what really happened last week.
The Reverse Total Hip — Promise, Perils, and the Data That Will Decide
We’ve all heard the drumbeat: total hip arthroplasty (THA) is a mature, commodity market. Implants are reliable, survival curves flatline
When the Race to the Bottom Lands You in the Power Tool Aisle
We often talk about implant “commoditization” in orthopedics. It’s that spooky campfire story that consultants use to scare medical sales
A quick dive into the 3 types of publicly traded Orthopedic companies.
Something different today. The orthopedic sector continues to showcase a fascinating divide of financial health. When looking at the public
Why Ortho innovation works better inside a Venture Studio
The traditional playbook for taking an idea to commercialization is broken. Historically, a surgeon has a great new product idea
Making sense of the ZB acquisition of iovera°
Tiger’s Strategic Summary ZB knows that implants are becoming commodities with an inevitable race to the bottom. ZB also knows
🔴 Tiger’s Red-Hot Innovator of the Week – Startup simplifying biceps tenodesis with sutureless anchor.
I believe that we are entering the Sports Med wave with accelerating innovation in this space. Below is my scoring of
[Tiger’s Weekly Intel] – Niche M&A, Startup Fundings, Pivots to AI Workflow and Localized Post-Surgical Pain Management.
Most of the industry is reading silly press releases, but here is your 7-day market update. Now that 2026 H1
Insights into the venture “bottom” for ortho innovators.
It’s been a rough few years for orthopedic innovators needed capital. My short summary of the capital allocators during this
Death of the Ortho Sales Rep (or how we lost our autonomy & our surgeons).
If you’ve been in the orthopedics game long enough, you remember the Golden Era. Thirty years ago, being an ortho
Why Ortho Startups Fail the Reimbursement Reality Test
What this article will teach you. Reimbursement isn’t a math problem; it’s a structural maze. Stop building your commercial strategy
The Equity Percentage Trap
You are looking at your offer letter from an early-stage orthopedic company. You can understand the base salary, the bonus
🔴 Tiger’s Red-Hot Innovator of the Week – Startup enhancing anchor outcomes with real-time AI Intelligence during surgery.
For decades, the sports medicine market has been defined by the same frustrating tradeoffs: mechanical weaknesses in repair setups, clunky
[Tiger’s Weekly Intel] – Mini-Tech, Micro-M&A, and Non-Invasive Interventions Disrupting Orthopedics
Most of the industry is reading silly press releases, but here is your 7-day market update. The shift continues. Ortho
How Silver Bullet is Weaponizing Healthcare Economics Against SSIs
We all know that surgical site infections (SSIs) are the ultimate nightmare in orthopedics. A flawlessly executed procedure can be
Inside the Quiet Ortho Revolution Happening North of the Border
For decades, the global orthopedic community has looked to the usual suspects for groundbreaking innovation: Warsaw, Indiana; Memphis, Tennessee; or
Before you sign: How to find hidden financial red flags at the company.
Joining a new orthopedic company is an exciting career move, but the medical device world carries unique financial risks. Long
Why independence won’t save DePuy Synthes
Johnson & Johnson will sell or spinout its $20B DePuy Synthes orthopedics business, and that tell-all number tells you absolutely
Tiger’s Red-Hot Innovator of the Week – Startup runs 30,000 digital simulations per patient to find the absolute perfect joint match.
Every Monday I share a startup that I really. I call it the Red-Hot Innovator of the Week. I am
[Tiger’s Weekly Intel] 👀 Big Ortho’s Broken R&D, $650M Cash Drops, and the Threat to the Legacy Robotics Footprint
Most of the industry is reading silly press releases, but here is your 7-day unredacted market update. The mega-trend in
Wearables Are About to Explode in Orthopedics
We all know that orthopedics lags other medical areas in real-time patient data collection. But that’s about to change. The
We all make bad hires. Learn the 5 reasons why we settle for B-players.
Your people are your company. Not your product pipeline, your regulatory clearances, your facility, or your capital. Your people. They
Cowboys vs. Ranchers in Ortho Sales
In ortho sales, we are told that people are divided into two groups: “hunters” who chase new business and “gatherers”
🔴 Tiger’s Red-Hot Innovator of the Week – Startup ushers in the Future of Joint Preservation with 3D-Printed, Lightweight Off-Loading Devices
Every Monday I share a startup that I really. I call it the Red-Hot Innovator of the Week. For decades,
👀 Caught My Eye (second week of June 2026)
Sharing a summary of orthopedic content that I consumed this week including some of the minor stories that you may